Ligand Pharmaceuticals Incorporated (LGNXZ)
OTCMKTS · Delayed Price · Currency is USD
0.0015
0.00 (0.00%)
At close: Aug 29, 2025
Ligand Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
| 187.58 | 167.13 | 131.31 | 196.25 | 241.54 | 163.56 | Upgrade | |
Revenue Growth (YoY) | 40.54% | 27.28% | -33.09% | -18.75% | 47.68% | 35.98% | Upgrade |
Cost of Revenue | 79.79 | 32.5 | 35.05 | 88.91 | 94.28 | 70.92 | Upgrade |
Gross Profit | 107.79 | 134.63 | 96.27 | 107.34 | 147.26 | 92.64 | Upgrade |
Selling, General & Admin | 89.06 | 78.65 | 52.79 | 70.06 | 46.79 | 39.31 | Upgrade |
Other Operating Expenses | - | - | - | - | - | 0.6 | Upgrade |
Operating Expenses | 122.09 | 111.61 | 86.44 | 104.3 | 81.01 | 51.55 | Upgrade |
Operating Income | -14.3 | 23.02 | 9.82 | 3.04 | 66.25 | 41.09 | Upgrade |
Interest Expense | -3.65 | -3.04 | -0.66 | -1.8 | -19.62 | -27.42 | Upgrade |
Interest & Investment Income | 6.67 | 8.06 | 7.71 | 2.05 | 0.89 | 8.08 | Upgrade |
Earnings From Equity Investments | -8.2 | -12.8 | - | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | -33.78 | -31.37 | -0.78 | -0.01 | -0.35 | 2.53 | Upgrade |
EBT Excluding Unusual Items | -53.25 | -16.13 | 16.1 | 3.28 | 47.17 | 24.28 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | - | -20.7 | Upgrade |
Gain (Loss) on Sale of Investments | -27.16 | 49.22 | 46.37 | 28.54 | -5.26 | -16.93 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 2.12 | - | - | 17.11 | Upgrade |
Asset Writedown | -4.08 | -30.57 | -0.92 | - | - | - | Upgrade |
Other Unusual Items | - | - | - | 4.19 | 30.3 | -2.47 | Upgrade |
Pretax Income | -84.5 | 2.52 | 63.66 | 36.01 | 72.21 | 1.29 | Upgrade |
Income Tax Expense | -8.63 | 6.55 | 9.84 | 41.23 | -4.15 | -5.31 | Upgrade |
Earnings From Continuing Operations | -75.86 | -4.03 | 53.82 | -5.22 | 76.35 | 6.6 | Upgrade |
Earnings From Discontinued Operations | - | - | -1.67 | -28.14 | -19.22 | -9.58 | Upgrade |
Net Income to Company | -75.86 | -4.03 | 52.15 | -33.36 | 57.14 | -2.99 | Upgrade |
Net Income | -75.86 | -4.03 | 52.15 | -33.36 | 57.14 | -2.99 | Upgrade |
Net Income to Common | -75.86 | -4.03 | 52.15 | -33.36 | 57.14 | -2.99 | Upgrade |
Shares Outstanding (Basic) | 19 | 18 | 17 | 17 | 17 | 16 | Upgrade |
Shares Outstanding (Diluted) | 19 | 18 | 18 | 17 | 17 | 17 | Upgrade |
Shares Change (YoY) | 5.60% | 3.00% | 5.27% | -2.19% | 2.50% | -14.84% | Upgrade |
EPS (Basic) | -4.00 | -0.22 | 3.02 | -1.98 | 3.44 | -0.18 | Upgrade |
EPS (Diluted) | -4.00 | -0.22 | 2.94 | -1.98 | 3.32 | -0.18 | Upgrade |
Free Cash Flow | 53.62 | 95.23 | 46.06 | 125.5 | 70.04 | 50.13 | Upgrade |
Free Cash Flow Per Share | 2.83 | 5.21 | 2.59 | 7.44 | 4.06 | 2.98 | Upgrade |
Gross Margin | 57.46% | 80.55% | 73.31% | 54.70% | 60.97% | 56.64% | Upgrade |
Operating Margin | -7.62% | 13.77% | 7.48% | 1.55% | 27.43% | 25.12% | Upgrade |
Profit Margin | -40.44% | -2.41% | 39.72% | -17.00% | 23.66% | -1.82% | Upgrade |
Free Cash Flow Margin | 28.58% | 56.98% | 35.07% | 63.95% | 29.00% | 30.65% | Upgrade |
EBITDA | 19.73 | 58.26 | 46.34 | 41.35 | 117.2 | 69.05 | Upgrade |
EBITDA Margin | 10.52% | 34.86% | 35.29% | 21.07% | 48.52% | 42.22% | Upgrade |
D&A For EBITDA | 34.03 | 35.24 | 36.52 | 38.32 | 50.95 | 27.97 | Upgrade |
EBIT | -14.3 | 23.02 | 9.82 | 3.04 | 66.25 | 41.09 | Upgrade |
EBIT Margin | -7.62% | 13.77% | 7.48% | 1.55% | 27.43% | 25.12% | Upgrade |
Effective Tax Rate | - | 260.13% | 15.46% | 114.49% | - | - | Upgrade |
Revenue as Reported | 167.13 | 167.13 | 131.31 | 196.25 | 241.54 | 163.56 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.